Table 1 Characteristics of the patients
From: An expression signature at diagnosis to estimate prostate cancer patients’ overall survival
Subset 1 | Subset 2 | Subset 3 | Complete set | |
|---|---|---|---|---|
FNA biopsies, n | 36 | 65 | 88 | 189 |
Mortality, n | ||||
Overall | 35 | 64 | 86 | 185 |
Death due to prostate cancer | 13 | 40 | 45 | 98 |
Death due to other causes | 19 | 21 | 25 | 65 |
Alive | 3 | 3 | 16 | 22 |
Missing | 1 | 1 | 2 | 4 |
Survival (years), median (range) | 7.7 (0.1–17.8) | 4.0 (0.2–15.7) | 4.3 (0.2–15.1) | 4.3 (0.1–17.8) |
Age (years), mean±s.d. | 70.4±7.8 | 72.1±8.7 | 73.8±8.9 | 72.6±8.7 |
Missing, n | 1 | 1 | 2 | 4 |
PSA (ng ml−1)a, n (%) | ||||
⩽20 | 9 (32.1) | 16 (31.2) | 23 (28.7) | 48 (29.8) |
> 20 and⩽50 | 9 (32.1) | 14 (26.4) | 23 (28.7) | 46 (28.6) |
> 50 | 10 (35.7) | 23 (43.4) | 34 (42.5) | 67 (41.6) |
Missing | 8 | 12 | 8 | 28 |
Clinical stageb, n (%) | ||||
Localized | 19 (59.4) | 27 (45.8) | 33 (39.3) | 79 (45.1) |
Advanced | 13 (40.6) | 32 (54.2) | 51 (60.7) | 96 (54.9) |
Missing | 4 | 6 | 4 | 14 |
WHO tumor grade, n (%) (level of differentiation) | ||||
Well/moderately | 22 (61.1) | 31 (50.0) | 33 (37.9) | 86 (46.5) |
Poorly | 14 (38.9) | 31 (50.0) | 54 (62.1) | 99 (53.5) |
Missing | 0 | 3 | 1 | 4 |
Treatment, n (%) | ||||
Never treated | 6 (19.4) | 2 (3.3) | 4 (4.9) | 12 (7.0) |
Hormone, orchiectomy | 19 (61.3) | 53 (88.3) | 62 (76.5) | 134 (77.9) |
Radiation | 5 (16.1) | 2 (3.3) | 11 (13.6) | 18 (10.5) |
Radical prostatectomy | 1 (3.2) | 3 (5.0) | 4 (4.9) | 8 (4.7) |
Missing | 5 | 5 | 7 | 17 |
